Using GANs for De Novo Protein Design Targeting Microglial IL-3R$\alpha$ to Inhibit Alzheimer's Progression
Arnav Swaroop

TL;DR
This study employs GANs and machine learning to design novel proteins targeting IL-3R, aiming to develop potential drugs that activate microglia and inhibit Alzheimer's progression by analyzing binding interactions.
Contribution
It introduces a de novo protein design approach using GANs to create novel IL-3 variants with potential therapeutic effects against Alzheimer's disease.
Findings
Designed proteins with similar secondary structures to IL-3 showed better binding in simulations.
Machine learning enabled the generation of novel protein structures for targeted binding.
Docking results identified promising candidates for further experimental validation.
Abstract
IL-3 is a hemopoietic growth factor that usually targets blood cell precursors; IL-3R is a cytokine receptor that binds to IL-3. However, IL-3 takes on a different role in the context of glial cells in the nervous system, where studies show that the protein IL-3 protects against Alzheimer's disease by activating microglia at their IL-3R receptors, causing the microglia to clear out the tangles caused by the build-up of misfolded Tau proteins. In this study, we seek to ascertain what role the secondary structure of IL-3 plays in its binding with the receptor. The motivation behind this study is to learn more about the mechanism and identify possible drugs that might be able to activate it, in hopes of inhibiting the spread of Alzheimer's Disease. From a preliminary analysis of complexes containing IL-3 and IL-3R, we hypothesized that the binding is largely due to the interactions of…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
Topics14-3-3 protein interactions
